Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
Journal of Crohn'S & Colitis|March 6, 2014
Biosimilars: in support of extrapolation of indicationsHans C EbbersDrug Discovery Today|June 30, 2019
Are we ready to close the discussion on the interchangeability of biosimilars?Hans C Ebbers, Huub SchellekensBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 14, 2016
Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling PracticesHans C Ebbers, Paul ChamberlainExpert Opinion on Biological Therapy|August 2, 2012
The safety of switching between therapeutic proteinsHans C Ebbers, Michael Muenzberg, Huub SchellekensClinical Pharmacology and Therapeutics|January 29, 2024
A Retrospective Analysis of the Potential Impact of Differences in Aggregates on Clinical Immunogenicity of Biosimilars and their Reference ProductsCristina Fernandez-Mendivil, Niamh M Kinsella, Hans C EbbersDrug Discovery Today|October 18, 2011
Effective pharmaceutical regulation needs alignment with doctorsHans C Ebbers, Toine Pieters, Hubert G Leufkens, et al.Expert Opinion on Biological Therapy|December 17, 2021
Current evidence on the use of the adalimumab biosimilar SB5 (ImraldiTM): a multidisciplinary perspectiveJavier P Gisbert, Karl Gaffney, David Young, et al.Rheumatology and Therapy|August 7, 2019
Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic ReviewHans C Ebbers, Burkhard Pieper, Amine Issa, et al.Clinical Pharmacology and Therapeutics|April 3, 2020
The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic ReviewLiese Barbier, Hans C Ebbers, Paul Declerck, et al.Drug Discovery Today|November 11, 2015
Characteristics of product recalls of biopharmaceuticals and small-molecule drugs in the USAHans C Ebbers, Nina Fuentes de Tienda, Marcel C Hoefnagel, et al.Pageof 3